GB9519737D0 - Polypeptides and their use in treatment and prophylaxis of auto-immune - Google Patents

Polypeptides and their use in treatment and prophylaxis of auto-immune

Info

Publication number
GB9519737D0
GB9519737D0 GBGB9519737.2A GB9519737A GB9519737D0 GB 9519737 D0 GB9519737 D0 GB 9519737D0 GB 9519737 A GB9519737 A GB 9519737A GB 9519737 D0 GB9519737 D0 GB 9519737D0
Authority
GB
United Kingdom
Prior art keywords
prophylaxis
polypeptides
immune
auto
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9519737.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Priority to GBGB9519737.2A priority Critical patent/GB9519737D0/en
Publication of GB9519737D0 publication Critical patent/GB9519737D0/en
Priority to AU70912/96A priority patent/AU7091296A/en
Priority to PCT/GB1996/002382 priority patent/WO1997011966A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9519737.2A 1995-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune Pending GB9519737D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9519737.2A GB9519737D0 (en) 1995-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune
AU70912/96A AU7091296A (en) 1995-09-27 1996-09-26 Polypeptides and their use in treatment and prophylaxis of auto-immune disease
PCT/GB1996/002382 WO1997011966A1 (en) 1995-09-27 1996-09-26 Polypeptides and their use in treatment and prophylaxis of auto-immune disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9519737.2A GB9519737D0 (en) 1995-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune

Publications (1)

Publication Number Publication Date
GB9519737D0 true GB9519737D0 (en) 1995-11-29

Family

ID=10781379

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9519737.2A Pending GB9519737D0 (en) 1995-09-27 1995-09-27 Polypeptides and their use in treatment and prophylaxis of auto-immune

Country Status (3)

Country Link
AU (1) AU7091296A (en)
GB (1) GB9519737D0 (en)
WO (1) WO1997011966A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724238A (en) * 2021-01-21 2021-04-30 浙江辉肽生命健康科技有限公司 Bioactive peptide with amino acid structure FREGTTPKPK, and preparation method and application thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
WO2001016174A2 (en) * 1999-08-30 2001-03-08 Rolf Kiessling Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
US7608683B2 (en) 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1652856A1 (en) * 2000-08-09 2006-05-03 The Regents of The University of California San Diego Stress proteins-derived peptides and method of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1575479A4 (en) 2002-01-31 2006-10-25 Develogen Israel Ltd Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
CU23504A1 (en) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
US10703784B2 (en) * 2011-09-30 2020-07-07 La Jolla Institute For Allergy And Immunology Antigens and epitopes derived from Mycobacterium tuberculosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338778C (en) * 1988-06-15 1996-12-10 Richard A. Young Stress proteins and uses therefor
DK0700445T3 (en) * 1993-06-04 2002-05-13 Whitehead Biomedical Inst Stress proteins and their applications
ATE260295T1 (en) * 1994-03-21 2004-03-15 Univ Utrecht PEPTIDE FRAGMENTS OF MICROBIAL STRESS PROTEINS AND PHARMACEUTICAL COMPOSITIONS PRODUCED THEREOF FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724238A (en) * 2021-01-21 2021-04-30 浙江辉肽生命健康科技有限公司 Bioactive peptide with amino acid structure FREGTTPKPK, and preparation method and application thereof

Also Published As

Publication number Publication date
WO1997011966A1 (en) 1997-04-03
AU7091296A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
PL322589A1 (en) Radiotracer-labelled peptides for use in diagnostics and therapy
EP0785276A4 (en) Modification of peptide and protein
EP0406428A4 (en) Peptide derivatives and their use
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
ZA947138B (en) Skin care method and composition
IL122216A0 (en) Dolastatin derivatives their preparation and use
GB9500856D0 (en) Composition and use
HUP9603373A3 (en) Cosmetic composition for artificial tanning and its use
AU3571095A (en) Polypeptides and their use in treatment and prophylaxis of auto-immune disease
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
GB9519737D0 (en) Polypeptides and their use in treatment and prophylaxis of auto-immune
GB2275029B (en) Improvements in and relating to wheelchairs
ZA943549B (en) Cell surface protein expressed on human cortical thymocyte and their use
GB2294637B (en) Therapeutic compositions and methods of use
ZA948463B (en) Treatment of cellulosic material and compositions for use in this
AU3752189A (en) Pharmaceutical compositions and use thereof in treating inflammation
GB2221464B (en) Oxaza heterocycles and their use in pharmaceutical compositions
AU7352396A (en) Use of protein S-100b in medicines and medicines containing the protein S-100-b
EP0841393A4 (en) HUMAN GALECTIN-4-LIKE PROTEIN AND cDNA ENCODING THE SAME
AU5042890A (en) Composition and treatment with peptide combinations
GB9517658D0 (en) Treatment of cellulosic material and compositions for use in this
ZA947139B (en) Skin care method and composition
EP0540575A4 (en) Human meg-csf protein and methods
GB9419549D0 (en) Polypeptides and their use in the treatment of auto-immune disease